<DOC>
	<DOCNO>NCT02273531</DOCNO>
	<brief_summary>Study establish bioequivalence new formulation Asasantin ER compare present commercially available Asasantin ER formulation ( Aggrenox® )</brief_summary>
	<brief_title>Bioequivalence New Asasantin Formulation Extended Release ( ER ) Compared Commercially Available Asasantin Formulation ( Aggrenox® ; Extended Release ) Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead ECG , clinical laboratory test : No find deviate normal clinical relevance No evidence clinically relevant concomitant disease Age ≥ 21 ≤ 65 year Body mass index ( BMI ) ≥ 18.5 ≤ 29.9 kg/m2 Signed date write informed consent prior admission study accordance good clinical practice ( GCP ) local legislation Able communicate well investigator comply study requirement Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 14 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre History frequent headache History gastrointestinal ulcer disease For female subject : Pregnancy Positive pregnancy test No adequate contraception e.g . oral contraceptive , sterilization , intrauterine device ( IUD ) Inability maintain adequate contraception whole study period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>